lifastuzumab vedotin (DNIB0600A) / Roche  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lifastuzumab vedotin (DNIB0600A) / Roche
NCT01363947: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Completed
1
87
US, Europe
DNIB0600A
Genentech, Inc.
Non-Small Cell Lung Cancer, Ovarian Cancer
06/16
06/16
NCT01995188: A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Completed
1
41
US
Bevacizumab, Avastin, Carboplatin, DNIB0600A
Genentech, Inc.
Non-Squamous Non-Small Cell Lung Cancer
11/16
11/16

Download Options